Merck Expects COVID-19 Pill Molnupiravir to Be Effective against Omicron

Reuters2022-01-11

Merck's COVID-19 oral pill molnupiravir has a mechanism of action that can work against Omicron and any other variant, a company executive said on Monday.

"We're very confident that it will effect Omicron ... This mechanism in molecule (will) work for Omicron, and I would imagine against any variant that comes up," Dean Li, president of Merck Research Laboratories, said at J.P. Morgan's annual healthcare conference.

Data on molnupiravir's impact against Omicron is not yet available, but the pill was shown to be 30% effective at reducing hospitalizations and deaths, based on data from 1,433 patients, as per latest data released in November.

However, this data showed significantly less effectiveness as compared to the previous figure of 50%.

The pill had received authorization from the U.S. Food and Drug Administration last month, as well as in several other countries like the UK, Japan and India, with various countries including U.S. signing agreements to buy the drug.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

PowerTrade
2022-01-11
PowerTrade
K
LLiM
2022-01-11
LLiM
[Sad]

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2202627093?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-11 08:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2202627093","market":"us","top_or_hot":-1,"title":"Merck Expects COVID-19 Pill Molnupiravir to Be Effective against Omicron","media":"Reuters","content":"<html><head></head><body><p>Merck&#39;s COVID-19 oral pill molnupiravir has a mechanism of action that can work against Omicron and any other variant, a company executive said on Monday.</p><p>&#34;We&#39;re very confident that it will effect Omicron ... This mechanism in molecule (will) work for Omicron, and I would imagine against any variant that comes up,&#34; Dean Li, president of Merck Research Laboratories, said at J.P. Morgan&#39;s annual healthcare conference.</p><p>Data on molnupiravir&#39;s impact against Omicron is not yet available, but the pill was shown to be 30% effective at reducing hospitalizations and deaths, based on data from 1,433 patients, as per latest data released in November.</p><p>However, this data showed significantly less effectiveness as compared to the previous figure of 50%.</p><p>The pill had received authorization from the U.S. Food and Drug Administration last month, as well as in several other countries like the UK, Japan and India, with various countries including U.S. signing agreements to buy the drug.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Expects COVID-19 Pill Molnupiravir to Be Effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Expects COVID-19 Pill Molnupiravir to Be Effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n2022-01-11 08:17 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck's COVID-19 oral pill molnupiravir has a mechanism of action that can work against Omicron and any other variant, a company executive said on Monday.\"We're very confident that it will effect ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"","article_id":"2202627093","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2202627093","pubTimestamp":1641860241,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Merck's COVID-19 oral pill molnupiravir has a mechanism of action that can work against Omicron and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东","BK4007":"制药","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4516":"特朗普概念"},"translate_title":"默沙东预计新冠肺炎药丸莫努匹拉韦对奥密克戎有效","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"Merck's COVID-19 oral pill molnupiravir has a mechanism of action that can work against Omicron and any other variant, a company executive said on Monday.\"We're very confident that it will effect Omicron ... This mechanism in molecule (will) work for Omicron, and I would imagine against any variant that comes up,\" Dean Li, president of Merck Research Laboratories, said at J.P. Morgan's annual healthcare conference.Data on molnupiravir's impact against Omicron is not yet available, but the pill was shown to be 30% effective at reducing hospitalizations and deaths, based on data from 1,433 patients, as per latest data released in November.However, this data showed significantly less effectiveness as compared to the previous figure of 50%.The pill had received authorization from the U.S. Food and Drug Administration last month, as well as in several other countries like the UK, Japan and India, with various countries including U.S. signing agreements to buy the drug.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9002010646,"gmtCreate":1641861461391,"gmtModify":1676533655757,"author":{"id":"3586141073754906","authorId":"3586141073754906","name":"PowerTrade","avatar":"https://static.tigerbbs.com/654a45b6f93ba0e4b1e1778ac7b45526","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586141073754906","idStr":"3586141073754906"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002010646","repostId":2202627093,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002034817,"gmtCreate":1641861221305,"gmtModify":1676533655709,"author":{"id":"3581561169225577","authorId":"3581561169225577","name":"LLiM","avatar":"https://static.tigerbbs.com/8fcbc1183a18838d98fbaaf0bcccc4df","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581561169225577","idStr":"3581561169225577"},"htmlText":"[Sad]&nbsp;","listText":"[Sad]&nbsp;","text":"[Sad]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002034817","repostId":2202627093,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":73,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2202627093"}